mon-te-LOO-kast

Therapeutic Classification: allergy, cold and cough remedies, bronchodilators

Pharmacologic Classification: leukotriene antagonists

• Prevention and chronic treatment of asthma.
• Seasonal or perennial allergic rhinitis (should only be used in patients with inadequate response or intolerance to other therapies).
• Prevention of exercise-induced bronchoconstriction.

• Antagonizes the effects of leukotrienes, which mediate the following:
  • Airway edema,
  • Smooth muscle constriction,
  • Altered cellular activity.
• Result is decreased inflammatory process, which is part of asthma and allergic rhinitis.

• Decreased frequency and severity of acute asthma attacks.
• Decreased severity of allergic rhinitis.
• Decreased attacks of exercise-induced bronchoconstriction.

Absorption: Rapidly absorbed (63–73%) following oral administration.

Distribution: Minimally distributed to tissues.

Protein Binding: 99%.

Metabolism/Excretion: Mostly metabolized by the liver by the CYP3A4 and CYP2C9 isoenzymes; metabolites eliminated in feces via bile; negligible renal excretion.

Half-life: 2.7–5.5 hr.

(improved symptoms of asthma)

†Plasma concentrations.

Contraindicated in:

• Hypersensitivity
• Acute attacks of asthma.

Use Cautiously in:

• Phenylketonuria (chewable tablets contain aspartame)
• Hepatic impairment (may need ↓ doses)
• Reduction of corticosteroid therapy (may ↑ the risk of eosinophilic conditions)
• Pedi: Children <6 yr (exercise-induced bronchoconstriction), <2 yr (seasonal allergic rhinitis), <12 mo (asthma), <6 mo (perennial allergic rhinitis) (safety and effectiveness not established).

Derm: rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS.

EENT: epistaxis, otitis (children), rhinorrhea, sinusitis (children).

GI: ↑liver enzymes, abdominal pain, diarrhea (children), dyspepsia, nausea (children).

Neuro: aggression, agitation, anxiety, attention disturbance, depression, disorientation, dream abnormalities, fatigue, hallucinations, headache, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, sleep walking, stuttering, SUICIDAL BEHAVIORS/THOUGHTS, tics, tremor, weakness.

Resp: cough.
Misc: (INCLUDING CHURG-STRAUSS SYNDROME)EOSINOPHILIC CONDITIONS , fever.

Drug-Drug:

• Levels and effectiveness may be ↓ by CYP3A4 or CYP2C9 inducers, including phenobarbital and rifampin.

Asthma

• PO (Adults and Children 15 yr): 10 mg once daily.
• PO (Children 6–14 yr): 5 mg once daily (as chewable tablet).
• PO (Children 2–5 yr): 4 mg once daily (as chewable tablet or granules).
• PO (Children 12–23 mo): 4 mg once daily (as granules).

Exercise-Induced Bronchoconstriction

• PO (Adults and Children 15 yr): 10 mg 2 hr before exercise. Do not take within 24 hr of another dose; if taking daily doses, do not take dose for exercise-induced bronchoconstriction.
• PO (Children 6–14 yr): 5 mg (as chewable tablet) 2 hr before exercise. Do not take within 24 hr of another dose; if taking daily doses, do not take dose for exercise-induced bronchoconstriction.

Allergic Rhinitis

• PO (Adults and Children 15 yr): Seasonal or perennial: 10 mg once daily.
• PO (Children 6–14 yr): Seasonal or perennial: 5 mg once daily (as chewable tablet).
• PO (Children 2–5 yr): Seasonal or perennial: 4 mg once daily (as chewable tablet or granules).
• PO (Children 6–23 mo): Perennial only: 4 mg once daily (as granules).

(Generic available)

• Tablets: 10 mg;
• Chewable tablets (cherry flavor): 4 mg; 5 mg;
• Oral granules: 4 mg/pkt;

• Assess lung sounds and respiratory function prior to and periodically during therapy.
• Assess allergy symptoms (rhinitis, conjunctivitis, hives) before and periodically during therapy.
• Monitor closely for changes in behavior that could indicate the emergence or worsening of depression or suicidal thoughts.
• Assess for rash periodically during therapy. May cause SJS. Discontinue therapy if severe or if accompanied with fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis, and/or eosinophilia.

• May cause ↑ AST and ALT.

• Doses of inhaled corticosteroids may be gradually decreased with supervision of health care professional; do not discontinue abruptly.
• PO: For asthma, administer once daily in the evening. For allergic rhinitis, may be administered at any time of day.
  • Administer granules directly into mouth or mixed in a spoonful of cold or room temperature foods (use only applesauce, mashed carrots, rice, or ice cream). Do not open packet until ready to use. After opening packet, administer full dose within 15 min. Do not store mixture. Discard unused portion. Do not dissolve granules in fluid, but fluid may be taken following administration. Granules may be administered without regard to meals.
  • For Exercise-Induced Bronchoconstriction: Administer one tablet at least 2 hr before exercise; do not take within 24 hr of another dose.

• Instruct patient to take medication daily in the evening or at least 2 hr before exercise, even if not experiencing symptoms of asthma. If dose is missed, omit and take next dose at regularly scheduled time; do not double doses. Do not discontinue therapy without consulting health care professional. Advise patient to read Patient Information before starting therapy and with each Rx refill in case of changes.
• Instruct patient not to discontinue or reduce other asthma medications without consulting health care professional.
• Advise patient that montelukast is not used to treat acute asthma attacks, but may be continued during an acute exacerbation. Patient should carry rapid-acting therapy for bronchospasm at all times. Advise patient to notify health care professional if more than the maximum number of short-acting bronchodilator treatments prescribed for a 24-hr period are needed.
• Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking any new medications.
• Encourage patient and family to be alert for emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, mania, worsening of depression and suicidal ideation, especially during early antidepressant therapy. Assess symptoms on a day-to-day basis as changes may be abrupt. If these symptoms or rash occurs, notify health care professional.
• Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

• Prevention of and reduction in symptoms of asthma.
• Decrease in severity of allergic rhinitis.
• Prevention of exercise-induced bronchoconstriction.

Singulair